- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01415544
Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References
An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Currently, individuals with diabetes must use an invasive finger stick methodology for the determination of their blood glucose levels. Although current technology glucose meters use a smaller amount of blood than older generation meters, the pain and inconvenience associated with this invasive measurement is the number one reason cited for inadequate or infrequent blood glucose monitoring. In fact up to 67% of patients with diabetes fail to routinely monitor their blood glucose levels. A survey of 1895 patients showed that finger soreness was the most common reason given for self-reported noncompliance with testing recommendations, followed by pain, inconvenience, fear of needles, and "other" (including cost), (Diabetes Care August 2001 vol. 24 no. 8 1502-1503). The ability to make a painless blood glucose measurement using only light would address the pain and inconvenience issues associated with current technology glucose meters.
The initial application of the technology is associated with the monitoring of Gestational Diabetes. The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recently released recommendations for diagnosing gestational diabetes, as well as clarifying the benefits of treatment (Diabetes Care, 2010;33:676-682). The IADPSG cited research that found significant graded relationships between increasing maternal glucose levels and the frequency of four primary and five secondary outcomes. For example, with a 1-standard deviation increase in maternal fasting, 1-hour, and 2-hour plasma glucose levels, there was a corresponding 38%, 46%, and 38% increased risk, respectively, in the primary outcome of birth weight >90th percentile, and a 5%, 18%, and 16% increased risk, respectively, of the secondary outcome of premature delivery before 37 weeks gestation (N Engl J Med 2008;358:1991-2002).
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Lovelace Scientific Resources
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Female at least 20 years of age but not older than 50 years of age
- Female with Type I or Gestational diabetes based on ADA criteria
- Female with Type II diabetes and A1c of greater than 7.0 as measured on a Bayer A1C Now meter
- May include female healthy volunteers.
Exclusion Criteria:
- Subject requires hemo-dialysis
- Severe heart disease as evidenced by peripheral edema
- Liver disease as evidenced by jaundice
- Active alcohol or drug abuse
- Body Mass Index (BMI) > 35 kg/m2
- Hand size too large to fit in the optical measurement instrumentation
- Middle finger width of less than 5 mm
- Skin damage at optical sampling site on hand
- Currently taking prednisone or other systemic steroids
- Tattoo at the optical sampling site
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Type 2 Diabetes
Those previously diagnosed with type 2 diabetes
|
Type 1 Diabetes
Those previously diagnosed with type 1 diabetes
|
Gestational Diabetes
Those that are currently diagnosed with gestational diabetes
|
Healthy Human Volunteers
Those that have not been diagnosed with any type of diabetes
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Calibrate near-infrared spectroscopy-based glucose meter
Tidsramme: 1 year
|
The collection of capillary blood glucose and noninvasive data will allow the calibration of the noninvasive systems and subsequently evaluate performance via a validation study.
The paired NIR spectrum and blood reference data acquired during calibration will be processed using multivariate regression techniques to create a calibration model.
Results will be compared using a Clark error grid.
|
1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Compare Noninvasive to invasive techniques
Tidsramme: 1 year
|
Comparison of noninvasive glucose measurement performance versus standard invasive reference.
Invasive measurements are made by obtaining capillary blood glucose measurements and then measuring blood on a Yellow Springs Instrument (YSI).
Due to the fact that instrumentation drift and subject physiological changes can adversely influence measurement performance, the study is specifically designed to examine performance over an appropriate period of time with a reasonable distribution of subject variance.
Results will be compared using a Clark error grid.
|
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Walter Forman, MD, Lovelace Scientific Resources
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 10-0020
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 1 diabetes
-
Oxford Brookes UniversityUniversity of OxfordAfsluttetFysisk aktivitet | Mental sundhed velvære 1 | Kognitiv funktion 1, Social | Academic Attainment | Fitness TestingDet Forenede Kongerige
-
Merck Sharp & Dohme LLCRekrutteringIkke-småcellet lungekræft | Faste tumorer | Programmeret celledød-1 (PD1, PD-1) | Programmeret celledød 1 Ligand 1 (PDL1, PD-L1) | Programmeret celledød 1 ligand 2 (PDL2, PD-L2)Japan
-
Alvotech Swiss AGAfsluttet
-
PfizerAfsluttet
-
Stony Brook UniversityAfsluttet
-
SanionaAfsluttet
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionAfsluttet
-
Calliditas Therapeutics ABAfsluttet
-
JKT Biopharma Co., Ltd.Rekruttering
-
Graviton Bioscience CorporationAfsluttet